Guselkumab in the treatment of concomitant hidradenitis suppurativa, psoriasis, and Crohn’s disease

Berman, Hannah; Villa, Natalie M.; Shi, Vivian Y.; Hsiao, Jennifer L.

doi:10.1080/09546634.2019.1654067

Cited by 36 publications

(41 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is approved for the treatment of moderate to severe psoriasis in adults. It has shown good results in Hurley Stage II or III HS patients, 4,5 with improvement after an average of 4.3 months; some of these patients had concomitant psoriasis 6‐8 . One randomized controlled trial evaluating the efficacy and safety of guselkumab in moderate to severe HS patients is underway 9…”

Section: Figurementioning

confidence: 99%

“…It has shown good results in Hurley Stage II or III HS patients, 4,5 with improvement after an average of 4.3 months; some of these patients had concomitant psoriasis. [6][7][8] One randomized controlled trial evaluating the efficacy and safety of guselkumab in moderate to severe HS patients is underway. 9 We are reporting herein a case of concomitant HS, paradoxical psoriasiform reaction to adalimumab and sacroiliitis that were successfully treated with guselkumab.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Sequential paradoxical psoriasiform reaction and sacroiliitis following adalimumab treatment of hidradenitis suppurativa, successfully treated with guselkumab

Garcia‐Melendo

Vilarrasa

Cubiró

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

Paradoxical reactions during treatment with a biologic agent are defined by the appearance or exacerbation of a pathological condition that usually responds to this drug while treating another condition. A 26-year-old woman presented with a 3-year history of Hurley Stage III hidradenitis suppurativa (HS) involving the groin, buttocks, and pubis, which had been refractory to topical antibiotics and corticosteroids, doxycycline, rifampicin, and clindamycin in combination. F I G U R E 1 Hurley stage III Hidradenitis suppurativa and paradoxical psoriasiform reaction to adalimumab. A,B, Inflammatory nodules and abscesses in the groin and pubis (Hurley Stage III, Physician's Global Assessment 4) together with erythemato-desquamative plaques on the legs and C, palms with pustules and D, extensive alopecia patches on the scalp secondary to desquamative plaques. Because of the severity of hair loss, the patient herself shaved the remaining hair and had to wear a wig.

show abstract

Section: Figurementioning

confidence: 99%

mentioning

confidence: 99%

Sequential paradoxical psoriasiform reaction and sacroiliitis following adalimumab treatment of hidradenitis suppurativa, successfully treated with guselkumab

Garcia‐Melendo

Vilarrasa

Cubiró

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…The remaining 11 patients all experienced improvement from treatment, with three patients being in remission from HS. Crohn's disease was present in one patient, which was diagnosed after HS 13 . No side effects from treatment with guselkumab were reported.…”

Section: Systematic Review Of the Literaturementioning

confidence: 93%

“…Crohn's disease was present in one patient, which was diagnosed after HS. 13 No side effects from treatment with guselkumab were reported.…”

Section: The Literaturementioning

confidence: 96%

See 1 more Smart Citation

Guselkumab for hidradenitis suppurativa in a patient with concomitant Crohn’s disease: Report and systematic literature review of effectiveness and safety

Jørgensen

Holm

Thomsen

2020

Clinical Case Reports

View full text Add to dashboard Cite

show abstract

Biologics and small molecule inhibitors for hidradenitis suppurativa

Shih

De²,

Shi

et al. 2022

Dermatological Reviews

Self Cite

View full text Add to dashboard Cite

Background: Hidradenitis suppurativa (HS) is a debilitating, chronic inflammatory dermatosis that is often recalcitrant to first-line treatments. Though mechanisms underlying its pathology remain unclear, a number of upregulated inflammatory cytokines (including tumor necrosis factor-α [TNF-α], interleukin [IL]-1, IL-17, IL-12, and IL-23) have been identified in HS, leading to a growing investigation of targeted biologic therapies in moderate-to-severe HS.Objective: We aim to review the current literature on biologics and small molecule inhibitors that have been used to treat HS and discuss mechanisms of action, dosing, safety considerations, and recommendations for use.

show abstract

Guselkumab in the treatment of concomitant hidradenitis suppurativa, psoriasis, and Crohn’s disease

Cited by 36 publications

References 16 publications

Sequential paradoxical psoriasiform reaction and sacroiliitis following adalimumab treatment of hidradenitis suppurativa, successfully treated with guselkumab

Sequential paradoxical psoriasiform reaction and sacroiliitis following adalimumab treatment of hidradenitis suppurativa, successfully treated with guselkumab

Guselkumab for hidradenitis suppurativa in a patient with concomitant Crohn’s disease: Report and systematic literature review of effectiveness and safety

Biologics and small molecule inhibitors for hidradenitis suppurativa

Contact Info

Product

Resources

About